{
  "trial_id": "NCT02488993",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Diagnosis of cirrhosis",
      "label": "unknown"
    },
    {
      "criterion": "Patient is \u226518 years of age",
      "label": "met"
    },
    {
      "criterion": "Patient is enrolled within 12 weeks of resolution of an episode of overt HE associated with a hospital visit",
      "label": "not_met"
    },
    {
      "criterion": "Patient is able to provide informed consent to participate in the study (individually or via caregiver)",
      "label": "met"
    },
    {
      "criterion": "Patient meets clinical eligibility to receive rifaximin-\u03b1 550 mg in the opinion of the participating physician, regardless of HE treatment actually received",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "West Haven Conn score of \u22652 at time of study entry (i.e. at provision of informed consent)",
      "label": "not_met"
    },
    {
      "criterion": "Mental health disorder such as dementia or psychosis which makes diagnoses of HE questionable",
      "label": "unknown"
    },
    {
      "criterion": "Prior treatment with rifaximin in the 12 months before qualifying episode of overt HE associated with a hospital visit",
      "label": "not_met"
    },
    {
      "criterion": "Contraindications to the use of rifaximin-\u03b1 as per local summary of product characteristics",
      "label": "unknown"
    }
  ],
  "notes": "Patient has had previous episodes of diabetic ketoacidosis, but appears well with this episode of hyperglycemia.",
  "_meta": {
    "topic_id": "29",
    "trial_id": "NCT02488993",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}